Education & Research

Clinical Studies

You are here

Evidence for Benefits of CGM Use

Recognized as a standard of care in diabetes management by the American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE) and the Endocrine Society,1,2,3 continuous glucose monitoring (CGM) use has proven to both reduce A1C and time spent in hypoglycemia regardless of delivery method.4,5 Regular CGM use is also associated with an increase of time spent in range,4,6 a reduction of severe hypoglycemic incidents,7,8 and associated with many behavioral changes that promote significant positive change in diabetes self-management.9

In hypoglycemia unaware patients, CGM provides the required information needed for enhanced decision making support to improve glycemic control and help eliminate severe hypoglycemia. In this observational study, severe hypoglycemia incidents...

In this open-label, single-arm, multicenter clinical study, the Dexcom G4® PLATINUM Continuous Glucose Monitoring (CGM) System (which uses the same software 505 as the Dexcom G5 Mobile CGM System) was evaluated for accuracy in 51...

Persistent use of a continuous glucose monitoring (CGM) system is tied to the sensor accuracy, particularly in the pediatric population who experience greater glycemic variability and wider glycemic excursions than adults. Clinical peformance...

In this first-of-its kind clinical trial, the benefit of continuous glucose monitoring (CGM) use by patients on multiple daily injections (MDI) insulin therapy was investigated. The evidence was resounding—patients on MDI demonstrated significant...

Published in 2008 by the Juvenile Diabetes Research Foundation (JDRF), results from this landmark randomized, controlled trial was the first study to provide clear evidence of improved glycemic outcomes with the use of continuous glucose...

In this novel study, investigators examined not only the benefits of continuous glucose monitoring (CGM) augmented insulin therapy, they also looked at the impact of CGM separately in subjects on multiple daily injection (MDI) regimen vs. insulin...

Pages

1

American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64.

2

Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring
Consensus Statement. Endocr Pract. 2016;22(2):231-261.

3

Peters A, Ahmann A, Battelino T et al. Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016:jc.2016-2534.

4

Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.

5

Battelino T PM, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2011;34(4):795-800.

6

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.

7

Choudhary P, Ramasamy S, Green L et al. Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care. 2013;36(12):4160-4162.

8

Lind M, Polonsky, W, Hirsch, I, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Injections – The GOLD Randomized Clinical Trial. [published January 2017]. JAMA.

9

Haas L, Maryniuk M, Beck J, et al. National Standards for Diabetes Self-Management Education and Support, Diabetes Care, Volume 35, November 2012